S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	HemaSphere
المؤلفون الرئيسيون:	Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J Luck, Daniela Weber, Isabelle Schneider, Andrea Corbacioglu, Verena I Gaidzik, Ekaterina Jahn, Nikolaus Jahn, Silke Kapp-Schwoerer, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S Götze, Thomas Kindler, Michael Lübbert, Richard F Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2023-08-01
الوصول للمادة أونلاين:	http://journals.lww.com/10.1097/01.HS9.0000967452.29390.a8

مواد مشابهة

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
حسب: Frank G. Rücker, وآخرون
منشور في: (2024-12-01)

Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
حسب: Sibylle Cocciardi, وآخرون
منشور في: (2025-01-01)

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
حسب: F. G. Ruecker, وآخرون
منشور في: (2022-06-01)

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
حسب: Katrin Teich, وآخرون
منشور في: (2021-05-01)

Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
حسب: Frank G. Rücker, وآخرون
منشور في: (2018-01-01)

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
حسب: Peter Paschka, وآخرون
منشور في: (2015-03-01)

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
حسب: Frank G. Rücker, وآخرون
منشور في: (2024-07-01)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
حسب: Susanne Hirsch, وآخرون
منشور في: (2017-12-01)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
حسب: Verena I. Gaidzik, وآخرون
منشور في: (2023-05-01)

MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses
حسب: Velizar Shivarov, وآخرون
منشور في: (2016-11-01)

Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations
حسب: Michael W.M. Kühn, وآخرون
منشور في: (2014-08-01)

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia
حسب: Annika C. Russ, وآخرون
منشور في: (2011-12-01)

Molecular characterization of acute myeloid leukemia
حسب: Konstanze Döhner, وآخرون
منشور في: (2008-07-01)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
حسب: Katherine Kelly, وآخرون
منشور في: (2023-08-01)

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
حسب: Haiyang Yun, وآخرون
منشور في: (2014-09-01)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
حسب: Jonas S. Heitmann, وآخرون
منشور في: (2023-08-01)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
حسب: Etienne Sollier, وآخرون
منشور في: (2023-08-01)

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
حسب: R. F. Schlenk, وآخرون
منشور في: (2023-09-01)

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
حسب: Richard F. Schlenk, وآخرون
منشور في: (2009-01-01)

P456: A LONG READ SEQUENCING AND CRISPR-CAS9 BASED APPROACH FOR RAPID COPY-NUMBER ALTERATION AND STRUCTURAL VARIATION DETECTION IN HEMATOLOGIC MALIGNANCIES
حسب: J. Schrezenmeier, وآخرون
منشور في: (2022-06-01)

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
حسب: Felicitas Thol, وآخرون
منشور في: (2015-04-01)

High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations
حسب: Frank Stegelmann, وآخرون
منشور في: (2010-04-01)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
حسب: Ian Edward Gentle, وآخرون
منشور في: (2021-07-01)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
حسب: Ekaterina Jahn, وآخرون
منشور في: (2023-08-01)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
حسب: Elizabeth Macintyre, وآخرون
منشور في: (2020-06-01)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
حسب: Maximilian Schmutz, وآخرون
منشور في: (2023-10-01)

Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
حسب: Christoph Rummelt, وآخرون
منشور في: (2023-01-01)

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
حسب: Marie-Luise Hütter-Krönke, وآخرون
منشور في: (2016-07-01)

P394: INSIGHTS INTO PATIENT-DERIVED XENOGRAFT MODELS FOR DEK-NUP214 LEUKEMIA
حسب: F. Charles Cano, وآخرون
منشور في: (2022-06-01)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction
حسب: Konstanze Döhner, وآخرون
منشور في: (2025-08-01)

A Rare Case of Midostaurin-Associated Sweet’s Syndrome
حسب: Hesham Yasin, وآخرون
منشور في: (2022-01-01)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
حسب: F. Stegelmann, وآخرون
منشور في: (2022-06-01)

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
حسب: Michael Lübbert, وآخرون
منشور في: (2012-03-01)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
حسب: Yanan Zhai, وآخرون
منشور في: (2022-08-01)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
حسب: Anna Riedel, وآخرون
منشور في: (2023-08-01)

The microRNA miR-196b acts as a tumor suppressor in Cdx2-driven acute myeloid leukemia
حسب: Vijay P. S. Rawat, وآخرون
منشور في: (2020-06-01)

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup
حسب: Markus Schaich, وآخرون
منشور في: (2007-06-01)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
حسب: Ning Ji, وآخرون
منشور في: (2019-06-01)

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
حسب: Johanna Thomas, وآخرون
منشور في: (2024-09-01)

Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin
حسب: Delia Soare, وآخرون
منشور في: (2025-07-01)